Latest News
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV
20 August 2026 - Clinical stage biotechnology company Annexin Pharmaceuticals AB (FN STO:ANNX) said on Thursday that the World Health Organization (WHO) has selected vanexin as the proposed International Nonproprietary Name (INN) for its drug candida...
Pillar Biosciences, LC-SCRUM-Asia and LSI Medience collaborate for liquid biopsy screening in lung cancer
20 August 2026 - US-based biotechnology company Pillar Biosciences Inc announced on Wednesday a collaboration with LC-SCRUM-Asia, a lung cancer screening project, and LSI Medience Corporation, a Japanese subsidiary of PHC Holdings Corporation, to sup...
Arcato reports positive Phase 1 trial results for ARC-001 Gel
20 August 2026 - Biotechnology company Arcato Laboratories Inc announced on Wednesday successful topline results from its first-in-human Phase 1 study of ARC-001 Gel in patients following third molar (wisdom tooth) extraction surgery.According to Arc...
Vascarta commences NIH phase I clinical study of VAS-101 in sickle cell disease
20 August 2026 - Pharmaceutical company Vascarta Inc announced on Wednesday that a second proof of concept phase I clinical study of VAS-101 (Vasceptor; topical curcumin gel) in sickle cell disease (SCD) is underway.Conducted at the National Institut...
Amplitude Therapeutics and Lilly collaborate on trans-amplifying RNA vaccine development for infectious diseases
20 August 2026 - Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, announced on Wednesday a strategic research collaboration and licensing agreement with Eli Lilly and Company (NYSE:LLY) t...